Mirion Acquires ec² Software Solutions, Expanding Nuclear Medicine, Molecular Imaging Portfolio
ATLANTA - Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, today announced the acquisition of ec2 Software Solutions, a U.S.-based developer of Nuclear Medicine and Molecular Imaging software, including the BioDose/NMIS and Numa platforms. ec2 Software Solutions becomes part of the Mirion Medical group of brands, joining Capintec, Dosimetry Services, and Sun Nuclear.
Headquartered in Las Vegas, NV, ec2 Software Solutions formed in 2011 through the merging of BioDose and NMIS. Building upon decades of service to the fields of Nuclear Medicine, Molecular Imaging, Nuclear Pharmacy, and PET Manufacturing, the combined organization specializes in the design, implementation, and support of software to simplify daily facility operations, including radiopharmaceutical production, distribution, and patient administration.
“I am pleased to welcome the ec2 team to the Mirion family, and to introduce Mirion to the ec2 customer community worldwide,” said Mirion CEO Thomas Logan. “Mirion and our Mirion Medical group are committed to ensuring seamless service and support for vital ec2 software as we invest in ongoing development and distribution.”
As part of Mirion Medical, ec2 Software Solutions will complement the Nuclear Medicine and Molecular Imaging portfolio of Capintec. The acquisition is consistent with Mirion’s strategic expansion plan focused on building its portfolio of industry-leading solutions across its Medical and Technologies segments.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “should,” “would,” “will,” “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include, but are not limited to, statements regarding the acquisition of the Critical Infrastructure business and Mirion’s ability to offer digital solutions to its customers. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including those described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in filings and reports we make from time to time with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,700 people and operates in 12 countries. Learn more at mirion.com.
For investor inquiries:
For media inquiries: